Allergy Therapeutics CEO on grass vaccine milestone and next steps

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet talked with Proactive's Stephen Gunnion about the granting of approval for Grassmuno, its grass allergy immunotherapy vaccine, in Germany - a significant milestone for the company. Llobet explained that the product is the first to be approved under the Therapieallergene-Verordnung (TAV) framework in the SCIT (subcutaneous immunotherapy) segment. The vaccine targets moderate to severe grass allergy sufferers, which he said represents the largest segment of the allergy market. "It's been a long journey, about one decade… tens of millions of investment to produce a state-of-the-art product," Llobet noted. He highlighted key advantages of the product: it is aluminium-free, adjuvanted, and designed as a short-course treatment — improving patient compliance and convenience. Allergy Therapeutics plans to replace its previous Pollinex Quattro Grass product in Germany with this new version, which has a higher concentration of active ingredients. Next steps include market expansion in Europe, Asia, and the US, leveraging clinical trials already coordinated with the FDA. The company is also exploring mutual recognition across EU territories via the Paul-Ehrlich-Institut. Llobet also touched on recent financials, pointing to portfolio restructuring and the shift from NPP products to registered treatments. Additionally, he discussed a potential dual primary listing in Hong Kong, aiming to engage Chinese investors and support expansion in the Asian market. Visit Proactive’s YouTube channel for more company interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications to stay updated. #AllergyTherapeutics #GrassAllergy #Immunotherapy #SCIT #BiotechNews #VaccineApproval #HealthInnovation #EuropeanHealthcare #FDA #HongKongListing #ClinicalTrials #AllergyVaccine #PharmaUpdates #InvestingInBiotech #ProactiveInvestors

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to discuss the company’s interim financial results for the fourth quarter and fiscal year ended September 30, 2025, highlighting a strong finish to the year driven by rising machine sales and expanding royalty streams. For the fourth quarter of fiscal 2025, EnWave reported revenue of C$6.2 million, a significant increase from C$3.6 million in the same quarter last year. The robust performance reflected the commissioning of one large-scale and six small-scale Radiant Energy Vacuum (REV™) machines, the sale of a refurbished 120-kilowatt unit, and continued fabrication work on two large-scale machines under existing contracts. Adjusted EBITDA for the quarter improved substantially to C$1.4 million, compared with C$0.45 million in Q4 2024. The improvement was attributed to higher machine sales volumes and a favorable production mix. Gross margin for the quarter also edged higher to 41%, up from 40% in the comparable period a year earlier. Royalty revenue showed mixed performance. Base royalties, excluding exclusivity payments, increased 31% to C$0.48 million, reflecting growing utilization of EnWave’s technology by partners. However, total royalty revenue declined 25% to C$0.48 million due to a royalty partner in a Central American market choosing not to renew an exclusivity agreement. For the full fiscal year 2025, EnWave posted revenue of C$13.8 million, up sharply from C$8.2 million in fiscal 2024. Adjusted EBITDA turned positive at C$0.3 million, compared with a loss of C$1.5 million in the prior year, driven primarily by increased machine sales. Annual gross margin improved to 34% from 33% in 2024. Base royalties for the year rose 14% to C$1.8 million, while total royalty revenue decreased slightly to C$1.95 million. Selling, general and administrative expenses, including research and development, increased to C$5.6 million as the company invested more heavily in marketing, sales, and growth initiatives. During the fourth quarter and subsequent months, EnWave signed multiple new equipment purchase and license agreements with partners including Milne MicroDried, Dairy Concepts, BranchOut Food, Solve Solutions, and Shinyway International, further expanding its commercial footprint. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #RadiantEnergyVacuum #Agritech #Procescir #DehydrationTechnology #FoodInnovation #SupplyAgreement #InvestmentNews #ProactiveInvestors #microdried

Nextech3D.ai CEO Evan Gappelberg and the company’s newly appointed Global Head of Sales, James McGuinness, joined Steve Darling from Proactive to discuss the strategic importance of McGuinness’ appointment as the company sharpens its focus on expanding commercial operations heading into 2026. Gappelberg explained that strengthening the sales organization is a critical pillar of Nextech3D.ai’s growth strategy as demand continues to rise for its AI-powered 3D, spatial computing, and event technology solutions. McGuinness has been brought in to lead the company’s global sales efforts, scale revenue-generating operations, and build a repeatable sales engine capable of supporting long-term growth. McGuinness brings more than 21 years of experience in enterprise and technology sales, with a proven track record of building and scaling sales teams at both early-stage startups and high-growth companies. Since joining Nextech3D.ai, he has already recruited two additional sales professionals, completing a fully staffed sales organization that blends long-tenured Nextech team members with experienced new hires. The company’s current sales team now includes a senior sales leader with a decade of industry experience, five of which have been spent at Nextech; a sales assistant with five years at the company; a sales engineer with four years of tenure; an additional seasoned sales representative; and two junior sales representatives focused on pipeline development and account support. McGuinness’ previous experience spans several well-known technology companies and successful exits. He was a founding salesperson for GeoTrust Europe prior to its acquisition by VeriSign, built and led sales development teams at SPSS Europe before its acquisition by IBM, and served as one of the founding salespeople at INXPO, an early pioneer in virtual event technology. He was also part of the founding sales team for LinkedIn Sales Navigator and played a key role in growing YCharts’ revenue from approximately $1.6 million to roughly $20 million before the company’s acquisition in 2020. Both Gappelberg and McGuinness emphasized that the strengthened sales leadership and fully built-out sales team position Nextech3D.ai to accelerate customer acquisition, deepen enterprise relationships, and capitalize on expanding market opportunities as the company moves into 2026. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #aws #amazonwebservice #tickets #kraftylab #jamesmcguinness

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce another major clinical milestone for the company, confirming that enrollment has been successfully completed in its Phase 2 clinical study evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA), also known as SKNJCT-003, for the non-invasive treatment of nodular basal cell carcinoma (BCC) of the skin. The Phase 2 study has enrolled a total of 90 patients across nine clinical sites in the United States and is currently underway. Completion of enrollment represents a key step forward in Medicus Pharma’s development strategy, positioning the company to advance discussions with regulators and accelerate progress toward later-stage trials. Dr. Bokhari explained that the company expects to report topline results from the SKNJCT-003 study in the first quarter of 2026. Following the release of these data, Medicus Pharma plans to pursue an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 to discuss the next steps in the clinical and regulatory pathway. SKNJCT-003 is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate two dose levels of the Doxorubicin Microneedle Array compared with a placebo microneedle array (P-MNA). Participants are randomized on a 1:1:1 basis into three treatment arms: a placebo group receiving P-MNA, a low-dose group receiving 100 micrograms of D-MNA, and a high-dose group receiving 200 micrograms of D-MNA. The high-dose 200 microgram D-MNA represents the maximum dose previously tested in the company’s Phase 1 safety and tolerability study, SKNJCT-001, which was successfully completed in March 2021. The Phase 2 trial builds on that foundation, aiming to further validate both safety and therapeutic effectiveness in a larger patient population. Medicus Pharma’s microneedle-based approach is designed to deliver chemotherapy directly into skin lesions while avoiding the need for invasive surgery, offering the potential for improved patient comfort, cosmetic outcomes, and treatment accessibility. The successful completion of enrollment marks a critical inflection point as the company advances toward potential late-stage development and regulatory engagement. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

C3 Metals CEO Dan Symons joined Steve Darling from Proactive to announce highly encouraging results from the first drill hole ever completed at the company’s Khaleesi copper project in southern Peru, marking a significant milestone for the greenfield exploration asset. The inaugural hole returned a broad intercept of 269.0 metres grading 0.30% copper, including a higher-grade interval of 60.4 metres at 0.41% copper starting from 346.0 metres downhole. Symons described the result as a strong validation of the geological model and a promising indication of scale for the emerging system. Khaleesi is currently being tested for the first time with an aggressive exploration program that includes two diamond drill rigs and a minimum of 6,000 metres of planned drilling. According to Symons, the early results point to the presence of a large, well-mineralized magnetite- and garnet-rich skarn body that is interfingered with multiple intrusive phases. The mineralized skarn–intrusive contact zone appears to be well defined, coinciding with strong chargeability and magnetic geophysical anomalies. Importantly, drilling has confirmed that copper mineralization extends beneath a broad area of shallow glacial till cover—an area that had not been previously drill-tested and which significantly expands the project’s exploration footprint. Symons cautioned that additional drilling will be required before the ultimate size and geometry of the Khaleesi system can be determined. In the meantime, the company is collecting detailed geological, alteration, geochemical, and structural data from all drill holes. This information is being incorporated into a comprehensive 3D geological block model, which will be integrated with existing 3D geophysical datasets to refine targeting and guide future drilling. Based on the strong results from hole KHZ5800-001 and positive visual observations from additional holes that are either completed and awaiting assay results or currently being drilled, C3 Metals is actively considering expanding the drill program beyond the originally planned 14-hole, 6,300-metre campaign. The early success at Khaleesi underscores the project’s potential to host a large-scale copper system and positions C3 Metals for continued exploration momentum as results continue to flow. #proactiveinvestors #c3metalsinc #tsxv #cccm #otcqb #cuauf #KhaleesiProject #CopperExplorat #PeruMining #GreenfieldExploration #DrillResults #CopperDiscovery #SkarnDeposit #BaseMetals #CriticalMinerals #MiningNews #ExplorationSuccess #DiamondDrilling #Geophysics #3DGeologicalModel #ResourceGrowth #CopperSupply #ProactiveInvestors

Blue Gold Limited CEO Andrew Cavaghan joined Steve Darling from Proactive to outline the company’s latest strategic initiatives, highlighted by a major move into the rapidly emerging tokenized gold market. Cavaghan confirmed that Blue Gold Ltd has signed a landmark agreement securing access to 1 million ounces of gold, with an estimated value of approximately US$4.5 billion. The gold will underpin the company’s planned tokenization strategy, allowing physical gold to be digitized and offered to the market as demand for gold-backed tokens grows. The supply agreement was established in partnership with DL Hudson Dunes, a long-established global commodities trading firm with operations spanning London, Singapore, and the United Arab Emirates. Cavaghan explained that the structure of the agreement provides flexibility, enabling Blue Gold to tokenize gold incrementally as market demand for the digital assets develops. In addition to the gold supply agreement, Cavaghan discussed Blue Gold’s proprietary trading arrangements, which provide upstream access to gold sources. This structure has the potential to generate more attractive margins and strengthens the company’s vertically integrated approach, combining physical gold exposure with innovative financial products. These strategic moves build on Blue Gold’s Nasdaq listing in June 2025 and reflect the company’s broader ambition to bridge traditional gold markets with the fast-evolving digital asset ecosystem. Cavaghan emphasized that tokenized gold offers investors the stability of a physical commodity with the accessibility and efficiency of blockchain-based assets. The interview also addressed Blue Gold’s mining operations in Ghana, where the company owns the Focus Mine, which hosts a reported 5.1 million-ounce gold resource. Cavaghan confirmed that a legal dispute regarding the mine’s title is ongoing. However, he noted that US$140 million has been placed in escrow and is available to restart production once the dispute is resolved. #proactiveinvestors #bluegoldlimited #nasdaq #bgl #GoldTokenization #BlueGoldLtd #DigitalAssets #GoldMining #TokenizedGold #AndrewCavaghan #CommodityTrading #NasdaqListing #GoldInvestment #DLHudsonDunes

Pathos Communications (LSE:NEWS) CEO Omar Hamdi talked with Proactive's Stephen Gunnion about the company’s mission to revolutionise media access for small and medium-sized enterprises (SMEs) through its proprietary AI tools. Hamdi outlined how Pathos Communications solves a long-standing issue in the PR space: getting SMEs into mainstream media coverage, a space typically dominated by billion-pound companies. With over 400 million SMEs globally, the company aims to scale impact through technology, not traditional PR methods. Pathos, recently named the fastest-growing communications firm in the UK by the Financial Times, is now a London-listed business. Hamdi highlighted that the decision to list was strategic: “We looked at all of the markets in the world, and we said, London’s the right place for us to be.” He also noted the rare backing of institutional investors, including Venture Capital Trusts. The firm’s roadmap includes scaling existing systems, global expansion into non-English-speaking markets, and advancing two internal AI tools: PathosMind, a PR brain for agencies, and Pressella, a virtual publicist for SMEs. “We believe that every business should have a full-time publicist,” said Hamdi. “The good news is you don’t have to pay $150,000 for one.” Watch the full interview for more on how Pathos plans to disrupt the global PR market. For more interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and hit the bell for notifications on new content. #PathosCommunications #OmarHamdi #AIPR #PublicRelations #SmallBusinessMarketing #SMEGrowth #AItools #ProactiveInvestors #LondonIPO #TechGrowth #Pressella #PathosMind

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s progress in its canine gene therapy trial targeting sarcopenia. Leire confirmed that the dosing phase has now been completed with no adverse effects, calling it a key milestone in de-risking the SIRT6 programme for potential pharma partners and investors. He said, “We demonstrated some kind of safety, with the full dosing, we had to observe no side effect, no adverse side effect, even minor event.” Leire explained the study’s scientific rigour, highlighting its randomised, controlled and blinded design using aged dogs not previously involved in clinical trials. This, he said, addresses a major unmet need in the life extension field, with industry experts previously considering such a study “impossible to do.” Looking ahead, efficacy data is expected in January, with analysis focused on multiple endpoints. These include mitochondrial function, clinical data, muscle biopsies, and epigenetic markers like the methylation clock in collaboration with UCLA. Leire said the results could influence other Genflow programmes, including preclinical work on NASH, Werner syndrome and ophthalmology. He noted that Genflow is in licensing discussions with several animal health companies and reiterated that while Genflow is not an animal health business, a potential deal could be shaped by the strength of the efficacy data. Visit Proactive’s YouTube channel for more exclusive interviews. Don’t forget to like this video, subscribe to the channel, and turn on notifications so you never miss an update. #GenflowBiosciences #SIRT6 #GeneTherapy #Sarcopenia #LifeExtension #CanineTrial #BiotechNews #PharmaDeals #AgeingResearch #BiotechInvesting #ClinicalTrials #MitochondrialFunction #BiotechUpdate #ProactiveInvestors

HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) executive chairman Frank Holmes talked with Proactive's Stephen Gunnion about the company's progress in both its Bitcoin mining operations and AI HPC initiatives. Holmes highlighted that the company has scaled its Bitcoin hash rate from 6 to 25 exahash over six months, a significant milestone that brings increased stability and improved margins. “We've hit that critical mass event where we have more stability and margins,” he said. He also noted the strategic benefit of sourcing only green energy, with HIVE supporting Paraguay’s infrastructure through the development of substations and employing local engineers. In November, the company mined 290 Bitcoin, representing an 8% increase month over month and a 180% increase year over year. Holmes positioned this performance as superior to Bitcoin’s price performance and that of peers in the sector. On the AI side, HIVE is seeing strong growth. Revenue has doubled in the past year and is expected to grow 5 to 6 times over the next 12 months. Holmes attributed this to the delivery of more Nvidia chips to data centers and a partnership with Bell Canada. He said the company is aiming for up to $140 million in AI-related revenue, with 10,000 clients worldwide already using or renting its services. Looking to 2026, HIVE plans to grow from 25 Eh to 35 Eh, with the Paraguayan government granting another 100MW of electricity. The company believes this could eventually expand to one gigawatt. Meanwhile, HIVE is repurposing a Bitcoin data center in Sweden into a high-performance computing hub, and sees strong potential at a site in New Brunswick, Canada. For more updates from leaders in crypto and tech, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications so you never miss an update. #HIVEDigital #BitcoinMining #AIHPC #CryptoInvesting #GreenEnergy #ParaguayMining #NvidiaChips #DataCenters #BlockchainTechnology #HighPerformanceComputing #CryptoNews #ProactiveInvestors

Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:PSGCF) CEO Robert Archer talked with Proactive's Stephen Gunnion about the company's first drill program at the El Potrero project in Mexico, which will start with underground drilling rather than surface work. Archer explained that the underground access available at El Potrero, due to historic mining that ceased 35 years ago, gives the company immediate access to mineralized zones. However, he pointed out the current workings are limited in extent, and only sampling what's visible on the walls and ceilings leaves uncertainty about the broader potential. He emphasized that, “you want to be able to blend the high grade and the low grade, such that you have a fairly consistent grade going to the plant,” highlighting the importance of understanding grade variability and distribution through drilling. This 112-hole delineation program will target three known zones within historic mines, while still leaving key areas between the mines and additional veins for future surface exploration. The underground results will contribute to a preliminary mine plan, including potential head grades and mining approaches. Looking ahead, a surface drill program will follow to explore other veins such as El Capulin, La Estrella, and Dos de Mayo, which have not been drilled previously. Visit Proactive’s YouTube channel for more exclusive interviews and updates. Don’t forget to like this video, subscribe to the channel, and hit the bell for notifications on future content. #PinnacleSilver #GoldExploration #SilverMining #ElPotrero #MiningMexico #JuniorMining #UndergroundDrilling #MiningStocks #NaturalResources #PreciousMetals